Browsing Tag
hepatitis delta virus
4 posts
How confirmatory trial pressure could shape the future of HDV treatment markets
FDA approval gave Hepcludex a major HDV breakthrough, but confirmatory trials may decide its long-term future. Read the full analysis.
How the cholestatic liver disease market is creating new opportunities for NTCP-targeting therapies
Assembly Biosciences is expanding ABI-6250 into PBC and PSC. Find out why NTCP-targeting therapies are gaining momentum in hepatology.
Mirum Pharmaceuticals (NASDAQ: MIRM) jumps 13% after VISTAS Phase 2b PSC win
Two Phase 2b wins in seven days. A pre-NDA meeting this summer. Mirum is starting to look less like a single-product rare disease story.
Gilead Sciences acquisition of MYR: A strategic move to tackle hepatitis delta virus
In a strategic acquisition aimed at expanding its hepatitis treatment portfolio, US biopharmaceutical giant Gilead Sciences has announced…